Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

Candel Therapeutics, Inc. (NASDAQ:CADL) on Wednesday revealed final survival data from a phase 2a trial of CAN-2409 in ...

CAN-2409, when administered with valacyclovir, is designed to induce ... by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor ...

every 8 hPrimary varicella: Acyclovir 10 mg/kg iv. every 8 h Valganciclovir 900 mg q.d. Ganciclovir 1 g p.o. t.i.d. Valacyclovir 2 g p.o. q.i.d. (for kidney recipients only)Pre-emptive therapy ...

The U.S. Food and Drug Administration (FDA) previously granted Fast Track Designation for CAN-2409 plus valacyclovir in combination with ICI treatment for the treatment of stage III/IV NSCLC in ...

The IDEA team will help guide Candel’s commercial strategy development and support the Company’s commercial projects related to CAN-2409. Through this partnership, Candel will gain access to a ...

CAN-2409 plus prodrug (valacyclovir) has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of PDAC, stage III/IV NSCLC in patients who are ...

CAN-2409 plus prodrug (valacyclovir) has been granted fast track designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor ...

CAN-2409 plus prodrug (valacyclovir) has been granted fast track designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor ...